Welcome to our dedicated page for Betterlife Pharma news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on Betterlife Pharma stock.
BetterLife Pharma Inc. develops BETR-001, a proprietary non-hallucinogenic derivative of LSD and neuroplastogen, for psychiatric and neurological disorders. News about BETRF commonly covers scientific updates on BETR-001’s mechanism of action and neuroplastogenic activity, intellectual property and regulatory-preparation disclosures, and disease areas such as traumatic brain injury, post-traumatic stress disorder, cluster headache, depression and anxiety.
Company updates also include strategic partnering and conference participation, development alternatives for its viral-infection therapeutic candidate, debt settlements and warrant exercises, board and advisory appointments, and public-company disclosure matters in Canada and the U.S. OTC market.
BetterLife Pharma Inc. announced approval from FINRA for its securities to be quoted on the OTC Markets under the symbol BETRF. This follows the company's compliance with Rule 15c2-11, marking a significant milestone in its U.S. market entry. CEO Dr. Ahmad Doroudian highlighted the company's commitment to developing therapeutic solutions, particularly in the fight against COVID-19. BetterLife is focused on creating drug candidates that utilize interferon-based technologies to combat viral infections and cancer. The PR also includes cautionary notes regarding forward-looking statements.